SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : 2021 Biotech Stock Picking Charity Contest -- Ignore unavailable to you. Want to Upgrade?

To: Aloner who wrote (95)1/28/2021 2:02:53 PM
From: Arthur Radley  Respond to of 307
 
This article about remdesivir, Gilead's drug, is going to open a can of worms. What is the answer--why should taxpayers pay more than $3,000.00 for using this drug if India can produce it for $300.00?

Remdesivir, Given to Half of Hospitalized Covid Patients in U.S., Is Big Win for Gilead — Boosted by Taxpayers | Kaiser Health News (khn.org)



To: Aloner who wrote (95)1/28/2021 9:32:48 PM
From: Julius Wong  Respond to of 307
 
Sorry. Wrong board.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News